泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03347 泰格医药

劳动节休市 04-30 16:08:17

26.750

+0.900

+3.48%

最高26.950	最低26.000	成交量185.02万
今开26.100	昨收25.850	日振幅3.68%
总市值231.37亿	流通市值32.90亿	总股本8.65亿
成交额4,912万	换手率1.50%	流通股本1.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":26.75,"timestamp":1746000497033,"preClose":25.85,"halted":0,"volume":1850201,"delay":0,"floatShares":123000000,"shares":864948570,"eps":0.5010104757088788,"marketStatus":"劳动节休市","change":0.9,"latestTime":"04-30 16:08:17","open":26.1,"high":26.95,"low":26,"amount":49119983,"amplitude":0.03675,"askPrice":26.75,"askSize":2900,"bidPrice":26.6,"bidSize":4400,"shortable":3,"etf":0,"ttmEps":0.4149072879568158,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":7,"adr":0,"listingDate":1596729600000,"exchange":"SEHK","adjPreClose":25.85,"dividendRate":0.011942,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"volumeRatio":0.730706,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":44.61,"timestamp":1745996400000,"preClose":44.48,"halted":0,"volume":6550300,"delay":0,"premium":"-43.81"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2531052981","title":"泰格医药回购股份方案实施期限届满","url":"https://stock-news.laohu8.com/highlight/detail?id=2531052981","media":"DoNews","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531052981?lang=zh_cn&edition=full","pubTime":"2025-04-30 23:16","pubTimestamp":1746026161,"startTime":"0","endTime":"0","summary":"4月30日，泰格医药发布公告称，公司回购股份方案实施期限已届满。截至当日，通过集中竞价交易方式累计回购9,806,300股，占总股本1.1337%。此举旨在优化资本结构并维护股东利益。免责声明：本文内容由开放的智能模型自动生成，仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043023242594e91e60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043023242594e91e60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","03347","BK1583","BK1576"],"gpt_icon":0},{"id":"2531051005","title":"泰格医药：本次回购股份方案的实施期限已届满","url":"https://stock-news.laohu8.com/highlight/detail?id=2531051005","media":"证券日报网","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531051005?lang=zh_cn&edition=full","pubTime":"2025-04-30 22:10","pubTimestamp":1746022200,"startTime":"0","endTime":"0","summary":"证券日报网讯4月30日晚间，泰格医药发布公告称，截至本公告日，公司本次回购股份方案的实施期限已届满，截至2025年4月30日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份9，806，300股，占公司总股本的比例为1.1337%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-04-30/doc-ineuyhur3986133.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-04-30/doc-ineuyhur3986133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1141","LU1146622755.USD","BK0077","300347","BK1576","BK1583","LU1820825898.SGD","03347","BK0216","BK0174","BK0028"],"gpt_icon":0},{"id":"2531035965","title":"康宁杰瑞制药-B(09966)：KN026关键性II/III期临床试验期中分析达到PFS主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2531035965","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531035965?lang=zh_cn&edition=full","pubTime":"2025-04-30 19:30","pubTimestamp":1746012652,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，本公司与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的KN026联合化疗二线及以上治疗HER2阳性GC的II/III期临床试验已完成首个期中分析及期中分析结果达到PFS主要终点。KN026-001研究第2部分的首个PFS期中分析结果已由独立数据监察委员会 审查，结果显示达到预先设定的PFS的主要终点，具有统计学显著性和临床意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1576","BK4211","03347","III","BK4195","BK1583","09966","BK4134","BK1574","BK1141","PFS"],"gpt_icon":0},{"id":"2531082764","title":"易方达基金增持泰格医药(03347)19.18万股 每股作价约26.98港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531082764","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531082764?lang=zh_cn&edition=full","pubTime":"2025-04-30 18:31","pubTimestamp":1746009071,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，4月25日，易方达基金增持泰格医药(03347)19.18万股，每股作价26.9807港元，总金额约为517.49万港元。增持后最新持股数目为871.81万股，持股比例为7.08%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0028","BK1141","03347","300347","BK0216","LU1146622755.USD","BK0174","LU1820825898.SGD","BK0077","BK1583"],"gpt_icon":0},{"id":"2531758084","title":"泰格医药截至4月末累计回购A股980.63万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531758084","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531758084?lang=zh_cn&edition=full","pubTime":"2025-04-30 18:04","pubTimestamp":1746007440,"startTime":"0","endTime":"0","summary":"泰格医药(03347)发布公告，截至2025年4月30日，公司股份回购专用证券账户...泰格医药(03347)发布公告，截至2025年4月30日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份980.63万股，占公司总股本的比例为1.1337%，占公司A股总股本比例为1.3219%，最高成交价为62.00元/股，最低成交价为48.17元/股，成交总金额为5亿元(不含交易费用)。公告称，公司本次实际回购资金总额已超过回购方案中的回购资金总额下限，且未超过回购资金总额上限，公司本次回购股份方案已实施完毕。追加内容本文作者可以追加内容哦 !","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043018071194e8d2fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043018071194e8d2fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","03347","BK1583","BK1141"],"gpt_icon":0},{"id":"2531839190","title":"泰格医药(03347)截至4月末累计回购A股980.63万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531839190","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531839190?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:28","pubTimestamp":1746005305,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，截至2025年4月30日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份980.63万股，占公司总股本的比例为1.1337%，占公司A股总股本比例为1.3219%，最高成交价为62.00元/股，最低成交价为48.17元/股，成交总金额为5亿元(不含交易费用)。公告称，公司本次实际回购资金总额已超过回购方案中的回购资金总额下限，且未超过回购资金总额上限，公司本次回购股份方案已实施完毕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03347","LU1820825898.SGD","LU1146622755.USD","399300","300347","BK0174","BK1583","159982","BK1576","BK0077","BK0028","BK0216"],"gpt_icon":0},{"id":"2531238085","title":"泰格医药04月30日主力净流入310.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2531238085","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531238085?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000925,"startTime":"0","endTime":"0","summary":"04月30日, 泰格医药股价涨3.48%，报收26.75元，成交金额4912.0万元，换手率1.50%，振幅3.68%，量比0.73。泰格医药今日主力资金净流入310.8万元，上一交易日主力净流出553.8万元。该股主力净额占比0.09%，港股市场排名77/2646。|04月30日主力加仓幅度排名||#|股票简称|主力净额占比|#|中国宏光|1.15%|#|中天湖南集团|1.03%|#|立德教育|1.00%|#|...|...|#76|泰格医药|0.09%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170521a46d7366&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170521a46d7366&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1141","03347","BK1576"],"gpt_icon":0},{"id":"2531703906","title":"默沙东研发（中国）有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2531703906","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531703906?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:27","pubTimestamp":1745998045,"startTime":"0","endTime":"0","summary":"4月30日，据CDE官网消息，默沙东研发（中国）有限公司联合申请药品“注射用MK-2870”，获得临床试验默示许可，受理号CXSB2500040。公示信息显示，药品“注射用MK-2870”适应症：非小细胞肺癌。默沙东研发（中国）有限公司，成立于2012年，位于北京市，是一家以从事研究和试验发展为主的企业。企业注册资本2000万美元，实缴资本2000万美元。通过天眼查大数据分析，默沙东研发（中国）有限公司参与招投标项目9次，专利信息3条，此外企业还拥有行政许可7个。主要股东信息显示，默沙东研发（中国）有限公司由默沙东研发有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/30152750039951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0265550359.USD","LU1989772840.SGD","LU0106261372.USD","LU0965509283.SGD","LU1037948897.HKD","BK4534","BK1576","LU0320765646.SGD","IE00BFTCPJ56.SGD","MRK","BK4516","LU1023059063.AUD","BK4007","LU0058720904.USD","BK4588","BK4585","SG9999014542.SGD","IE00BLSP4452.SGD","LU0289739699.SGD","LU0965508806.USD","LU0861579265.USD","LU0070302665.USD","LU1291159041.SGD","LU2089984988.USD","SG9999002224.SGD","LU1057294990.SGD","LU1941712264.USD","LU1035773651.USD","LU2461242641.AUD","LU1116320737.USD","LU0211331839.USD","LU1941712348.USD","LU1974910355.USD","SG9999001176.USD","LU1917777945.USD","BK4533","IE00BN8TJ469.HKD","IE00B1BXHZ80.USD","SG9999014575.USD","LU0203347892.USD","LU1066051811.HKD","LU1571399168.USD","LU2023250843.SGD","SG9999014567.USD","LU2023250504.SGD","LU0122379950.USD","LU1430594728.SGD","03347","LU1066053197.SGD","LU1093756325.SGD"],"gpt_icon":0},{"id":"2531039287","title":"北京泰德制药股份有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2531039287","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531039287?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:27","pubTimestamp":1745998045,"startTime":"0","endTime":"0","summary":"4月30日，据CDE官网消息，北京泰德制药股份有限公司联合申请药品“TCC1727片”，获得临床试验默示许可，受理号CXHL2500225。公示信息显示，药品“TCC1727片”适应症：本品适用于联合贝莫苏拜单抗注射液、奥拉帕利片或化疗治疗晚期实体瘤。北京泰德制药股份有限公司，成立于1995年，位于北京市，是一家以从事医药制造业为主的企业。企业注册资本50000万人民币，实缴资本50000万人民币。通过天眼查大数据分析，北京泰德制药股份有限公司共对外投资了13家企业，参与招投标项目5000次，知识产权方面有商标信息386条，专利信息213条，此外企业还拥有行政许可108个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/30152750039948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","BK1141","01477","03347","BK1574","BK1583","BK1576"],"gpt_icon":0},{"id":"1156609182","title":"港股异动 | 生物技术股走强，康希诺生物涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156609182","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156609182?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:13","pubTimestamp":1745982808,"startTime":"0","endTime":"0","summary":"4月30日，港股生物技术股盘中走强，$康希诺生物(06185)$涨超10%，$百济神州(06160$涨超6%，$诺诚健华(09969)$涨超4%，$泰格医药(03347)$涨超3%。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","03347","06160","09969"],"gpt_icon":0},{"id":"2531726021","title":"港股生物技术股多数走强，康希诺生物(06185.HK)涨超10%，百济神州(06160.HK)涨超6%，诺诚健华(099","url":"https://stock-news.laohu8.com/highlight/detail?id=2531726021","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531726021?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:11","pubTimestamp":1745982713,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1576","BK1500","HSTECH","BK0028","BK0077","688428","LU0588546209.SGD","BK1588","06160","06185","LU1820825898.SGD","LU1969619763.USD","LU2328871848.SGD","BK0216","BK4614","BK4139","BK1141","BK1515","BK1574","09969","300347","07226","YANG","688235","LU1146622755.USD","ONC","BK1583","BK0239","BK1161","HSCEI","03347","LU0307460666.USD","BK1191","BK0174"],"gpt_icon":0},{"id":"2531712894","title":"泰格医药（300347）2025年一季报简析：净利润减29.61%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2531712894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531712894?lang=zh_cn&edition=full","pubTime":"2025-04-30 07:08","pubTimestamp":1745968108,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泰格医药发布2025年一季报。截至本报告期末，公司营业总收入15.64亿元，同比下降5.79%，归母净利润1.65亿元，同比下降29.61%。本报告期泰格医药三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达37.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000009193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300347","03347"],"gpt_icon":1},{"id":"2531736659","title":"方盛制药最新公告：小儿荆杏止咳颗粒成人急性气管-支气管炎（风寒化热证）获得II期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736659","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531736659?lang=zh_cn&edition=full","pubTime":"2025-04-29 20:40","pubTimestamp":1745930425,"startTime":"0","endTime":"0","summary":"方盛制药(603998.SH)公告称，公司研发的小儿荆杏止咳颗粒取得了成人急性气管-支气管炎（风寒化热证）的临床试验II期临床研究总结报告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900038883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1583","BK1576","BK0239","BK0060","603998","BK1141"],"gpt_icon":0},{"id":"2531204633","title":"泰格医药(03347)将于7月31日派发末期股息每10股3元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531204633","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531204633?lang=zh_cn&edition=full","pubTime":"2025-04-29 17:54","pubTimestamp":1745920486,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，将于2025年7月31日派发截至2024年12月31日止年度的末期股息每10股3元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300347","LU1820825898.SGD","BK0174","LU1146622755.USD","BK1141","BK0028","03347","BK1576","BK0216","BK1583","BK0077"],"gpt_icon":0},{"id":"2531902226","title":"港股异动 | 科伦博泰生物-B(06990)午后涨超9% 美国FDA近日批准SKB518新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2531902226","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531902226?lang=zh_cn&edition=full","pubTime":"2025-04-29 14:20","pubTimestamp":1745907636,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B午后涨超9%，截至发稿，涨8.53%，报328.2港元，成交额2.46亿港元。消息面上，科伦博泰生物此前发布公告，公司已获得美国FDA批准启动其创新抗体偶联药物药物SKB518临床研究的新药临床试验申请。于2024年6月，公司收到国家药品监督管理局药品审评中心批准SKB518用于晚期实体瘤的IND申请的临床试验通知书。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1141","LU0196878994.USD","BK1583","BK1576","06990","BK1161"],"gpt_icon":0},{"id":"2531402062","title":"石药集团SYH2068注射液获临床试验批准，早盘涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531402062","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531402062?lang=zh_cn&edition=full","pubTime":"2025-04-29 13:06","pubTimestamp":1745903162,"startTime":"0","endTime":"0","summary":"4月29日，石药集团早盘上涨4.47%，现报6.31港元。其自主研发的化学1类新药SYH2068注射液（双链小干扰RNA药物）获国家药监局批准开展临床试验。该药物通过靶向脂蛋白（a），以皮下给药方式降低Lp（a）水平，适用于高脂蛋白（a）血症治疗。相比同类产品，其具有更持久的基因沉默效果和更高安全性，有望预防动脉粥样硬化性心血管疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042913070694e6f4c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042913070694e6f4c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1008478684.HKD","LU0501845795.SGD","LU1226287875.USD","LU1226288253.USD","03347","LU0067412154.USD","LU1993786604.SGD","IE0008369823.USD","BK1515","BK1521","SG9999004220.SGD","BK1191","LU0072913022.USD","IE00B543WZ88.USD","01093","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU0140636845.USD","LU0880133367.SGD","LU1226287792.SGD","LU1960683339.HKD","IE0008368742.USD","BK1141","LU1951186391.HKD","BK1583","IE00BZ08YT58.USD","LU1152091168.USD","LU1226288170.HKD","LU1807302812.USD","BK1576","IE00B5MMRT66.SGD","LU1226287529.USD"],"gpt_icon":0},{"id":"2531248950","title":"港股异动 | 泰格医药(03347)绩后跌超3% 一季度归母净利同比减少近三成 机构指其毛利率水平仍有提升空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2531248950","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531248950?lang=zh_cn&edition=full","pubTime":"2025-04-29 11:14","pubTimestamp":1745896478,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，泰格医药绩后跌超3%，截至发稿，跌2.45%，报25.95港元，成交6050.58万港元。消息面上，4月28日，泰格医药发布公告，于2025年第一季度，该集团取得营业收入15.64亿元，同比减少5.79%;归属于上市公司股东的净利润1.65亿元，同比减少29.61%;基本每股收益0.19元。此外，公司SMO业务较佳的订单支撑和效率优化下，毛利率水平仍有提升空间，实验室服务伴随着产能利用率爬坡，有望逐渐提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK1576","LU1146622755.USD","BK1141","03347","BK1583","LU1820825898.SGD","BK0216","BK0174","300347","BK0028"],"gpt_icon":0},{"id":"2531545216","title":"港股异动 | 石药集团(01093)涨超3% SYH2068注射液(双链小干扰RNA药物)获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2531545216","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531545216?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:42","pubTimestamp":1745890923,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团涨超3%，截至发稿，涨3.48%，报6.25港元，成交额1.77亿港元。消息面上，近日，石药集团发布公告，本集团自主研发的化学1类新药SYH2068注射液(该产品)已获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。临床前研究显示，该产品在药物活性和药效持续性方面优于同类型si RNA产品，展现出药物作用效果持久、安全性好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1191","LU1226287792.SGD","LU0880133367.SGD","RNA","IE00BZ08YS42.EUR","LU0072913022.USD","BK1576","LU1951186391.HKD","BK1583","LU1993786604.SGD","BK4585","01093","BK1515","LU1960683339.HKD","LU1226287875.USD","LU1226288170.HKD","BK1521","IE00B543WZ88.USD","LU1226287529.USD","LU0067412154.USD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1807302812.USD","LU1152091168.USD","BK4139","BK4505","LU0140636845.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","IE00B031HY20.USD","LU1226288253.USD","IE0008368742.USD","BK4588","03347","LU1008478684.HKD","IE0008369823.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2531211983","title":"石药集团涨超3% SYH2068注射液(双链小干扰RNA药物)获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2531211983","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531211983?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:42","pubTimestamp":1745890920,"startTime":"0","endTime":"0","summary":"石药集团SYH2068注射液获批临床试验，该双链小干扰RNA药物可降低脂蛋白(a)水平，预防动脉粥样硬化，临床前研究显优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042909511794e6b3f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042909511794e6b3f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","IE00BZ08YR35.GBP","LU1226287875.USD","LU1951186391.HKD","BK1191","LU0326950275.SGD","IE00BZ08YS42.EUR","LU1008478684.HKD","LU1152091168.USD","LU1226288253.USD","LU1807302812.USD","LU1226287792.SGD","IE00BZ08YT58.USD","LU1226288170.HKD","LU1226287529.USD","IE00B031HY20.USD","LU0067412154.USD","BK1515","03347","LU1152091754.HKD","BK1521","LU0140636845.USD","01093","BK1583","LU1993786604.SGD","LU0072913022.USD","LU0880133367.SGD","IE00B5MMRT66.SGD","LU0501845795.SGD","IE00B543WZ88.USD","LU1960683339.HKD","IE0008369823.USD","IE0008368742.USD","SG9999004220.SGD","BK1576"],"gpt_icon":0},{"id":"2531290744","title":"金十数据整理：每日港股市场要闻速递（4月29日 周二）","url":"https://stock-news.laohu8.com/highlight/detail?id=2531290744","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531290744?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:04","pubTimestamp":1745888643,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1141","LU2097828631.EUR","BK0028","603259","BK0188","BK0077","LU0327786744.USD","BK1583","LU1997245177.USD","600999","00991","LU1515016050.SGD","03908","02331","601991","300347","601995","LU0456842615.SGD","BK0271","07226","BK1502","BK1564","BK1578","LNNGY","HSTECH","BK0183","02359","06099","LU1146622755.USD","LU1188198961.HKD","00386","YANG","01918","LU0048580855.USD","LU0140636845.USD","BK1226","HSCEI","BK1501","82331","00168","LU1048588211.SGD","LU0359201612.USD","LU1051768304.USD","BK0276","LU0541501648.USD","LU1997244956.HKD","LU0072462343.USD","03347","BK1512","BK1147"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.1371},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.26},{"period":"1year","weight":-0.2157},{"period":"ytd","weight":-0.1315}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0433},{"period":"3month","weight":0.0937},{"period":"6month","weight":0.0787},{"period":"1year","weight":0.2452},{"period":"ytd","weight":0.1027}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.098232},{"month":2,"riseRate":0.6,"avgChangeRate":0.033576},{"month":3,"riseRate":0.6,"avgChangeRate":-0.015339},{"month":4,"riseRate":0.2,"avgChangeRate":-0.055131},{"month":5,"riseRate":0.25,"avgChangeRate":-0.024615},{"month":6,"riseRate":0.5,"avgChangeRate":-0.01435},{"month":7,"riseRate":0.5,"avgChangeRate":-0.014965},{"month":8,"riseRate":0,"avgChangeRate":-0.073433},{"month":9,"riseRate":0.4,"avgChangeRate":0.041739},{"month":10,"riseRate":0.4,"avgChangeRate":-0.034537},{"month":11,"riseRate":0.4,"avgChangeRate":0.029037},{"month":12,"riseRate":0.4,"avgChangeRate":0.033557}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}